It was the moment football held its breath. Christian Eriksen, a Danish playmaker, collapsed on the pitch at Euro 2020. Cameras looked away. The world looked on. And then, quietly, efficiently, a piece of British medical engineering did its job: a tiny subcutaneous implantable cardioverter-defibrillator, or S-ICD, a device developed and perfected in the UK, delivered a precisely timed shock that brought a dying heart back to life.
For those of us accustomed to the theatre of headlines, this story has all the ingredients of a medical thriller. But what strikes me, as I watch the replays and read the statements, is not the drama. It is the ordinariness of the heroism. The S-ICD, about the size of a small biscuit, sits beneath the skin, monitoring the heart for dangerous rhythms. It does not need wires piercing the blood vessels. It works from the outside in. And it has changed the calculus of cardiac arrest for athletes and ordinary people alike.
Eriksen’s case is not an isolated miracle. It is the fruit of decades of research, clinical trials, and sheer stubbornness by British cardiologists and engineers. The device was first conceptualised in London and refined in Bristol. It was tested on patients who had already run out of options. It was rejected by sceptics who said it could not work. And yet, here it is, saving a man in his prime on the biggest stage in sport.
But let us step back from the heroics. What does this mean for the rest of us? Every year, thousands of people in the UK alone suffer sudden cardiac arrest. For many, the first symptom is death. The S-ICD offers a second chance, a piece of insurance against the chaos of biology. It is not cheap, but it is cheaper than a lifetime of grief. And it is now being rolled out across the NHS, slowly, incrementally, as funding allows.
There is a deeper cultural shift here too. For too long, British innovation has been sold as a story of decline: shrinking budgets, exodus of talent, lost patents. But the Eriksen moment reminds us that we still know how to make things that matter. The device is a product of the British health system: a collaboration between universities, hospitals, and a homegrown company called Boston Scientific. Yes, it is now owned by an American firm, but the DNA is ours. The thinking happened here.
Yet the human cost nags. Only a fraction of those who could benefit from an S-ICD will ever receive one. The waiting lists are long. The criteria are strict. And for every Eriksen, there are thousands of unnamed people who collapse in their kitchens or on their morning runs, whose hearts do not restart because the device was not available, not fitted, not funded. The triumph of one is a rebuke to the system that let so many others slip away.
Still, let us not sour the moment. Eriksen is alive. He is playing football again. And the little machine that saved him is a quiet testament to what happens when we invest in the unglamorous, incremental work of saving lives. It does not make the front pages often. But when it does, we should pay attention. Because this is not just a story about a footballer. It is a story about us, about what we value, and about the tiny machines that one day might save your life too.
